Is CorVel (CRVL) overvalued or fairly valued?

MarketChacha shows CorVel's valuation in context — a trailing P/E of about 31.7, a price-to-book of about 8.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does CorVel's reported profit turn into cash?

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.33×) from reported figures — education, not a rating.

What is CorVel's revenue?

CorVel reported revenue of $958.5M for FY2026, with net profit of $110.3M, per official filings.

What is the share price of CorVel (CRVL)?

CorVel last traded at $68.58 (-0.2% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

CorVel

CRVL · NYSE · Healthcare · United States

Snapshot

TickerCRVL

ExchangeNYSE

SectorHealthcare

IndustryInsurance Brokers

CountryUnited States

Employees5,239

HeadquartersFort Worth, United States

Websitewww.corvel.com

Filings tracked13

About CorVel

CorVel Corporation provides workers' compensation, general and auto liability, and hospital bill auditing and payment integrity solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing; preferred provider management and reimbursement; retrospective utilization, facility claim, and professional review; pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions. In addition, it provides a range of patient management services, such as claims management customers, case management, 24/7 nurse triage, utilization management, vocational rehabilitation, and life care planning, as well as processing of claims for self-insured payors with respect to property and casualty insurance. The company offers solutions to employers, third party administrators, insurance companies, and government agencies to assist them in managing the medical costs and monitoring the quality of care associated with healthcare claims. CorVel Corporation was incorporated in 1987 and is based in Fort Worth, Texas.

Who owns it

Insiders39.4%
Institutions56.2%
Public & other4.4%

396 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.10.08%
Kayne Anderson Rudnick Investment Management LLC8.92%
Vanguard Portfolio Management LLC3.37%
Renaissance Technologies, LLC3.00%
Vanguard Capital Management LLC2.55%
State Street Corporation2.53%
Dimensional Fund Advisors LP2.23%
Geode Capital Management, LLC1.99%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.33×

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend9.2% → 11.5%

Margin has expanded by about 2.3 points — the business is getting more profitable.

Return on equity28.0%

Latest ROE of 28.0% — capital is generating a healthy return.

Growth qualityrev 10% · PAT 18%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2026)

$958.5M

Net margin

11.5%

ROE

28.0%

Revenue CAGR (3y)

+10.1%

Profit CAGR (3y)

+18.5%

EPS (FY2026)

2.14

Net profit (FY2026)

$110.3M

Ask MarketChacha about CRVL

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2026	$958.5M	$110.3M	2.14	11.5%	28.0%
FY2025	$895.6M	$95.2M	1.83	10.6%	29.6%
FY2024	$795.3M	$76.3M	1.47	9.6%	30.8%
FY2023	$718.6M	$66.4M	1.26	9.2%	32.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$259.9M	$32.2M	0.63	12.4%
2025Q4	$235.6M	$24.2M	0.47	10.3%
2025Q3	$239.6M	$27.9M	0.54	11.6%
2025Q2	$234.7M	$27.2M	0.52	11.6%
2024Q4	$228.0M	$23.8M	0.46	10.4%
2024Q3	$224.4M	$23.4M	0.45	10.4%
2024Q2	$211.7M	$21.6M	0.42	10.2%
2024Q1	$207.2M	$19.5M	1.12	9.4%
2023Q4	$202.3M	$17.1M	0.33	8.5%
2023Q3	$195.5M	$19.9M	1.15	10.2%
2023Q2	$190.3M	$19.8M	1.14	10.4%
2023Q1	$185.4M	$18.2M	1.04	9.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/6/2026
8-K — Results of operations, Exhibits
SEC8/5/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/1/2026material
10-K filing
SEC5/22/2026
8-K — Results of operations, Exhibits
SEC5/20/2026material
10-Q filing
SEC2/5/2026
8-K — Results of operations, Exhibits
SEC2/3/2026material

2025

10-Q filing
SEC11/6/2025
8-K — Results of operations, Exhibits
SEC11/4/2025material
8-K — Executive/director change
SEC9/12/2025material
8-K — Shareholder vote results
SEC8/13/2025material
10-Q filing
SEC8/7/2025
8-K — Results of operations, Exhibits
SEC8/5/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.